Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)

Rabbit Recombinant Monoclonal CXCL9 antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P, Flow Cyt (Intra) and reacts with Human samples.

Be the first to review this product! Submit a review

Images

Western blot - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (AB290654), expandable thumbnail

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.2 - 7.4
Constituents: 100% PBS
Form: Liquid
Clonality: Monoclonal

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application

Product promiseTestedExpectedPredictedNot recommended

	ICC/IF	IP	WB	IHC-P	Flow Cyt (Intra)
Human	Tested	Tested	Tested	Tested	Tested
Mouse	Not recommended	Not recommended	Not recommended	Not recommended	Not recommended
Rat	Not recommended	Not recommended	Not recommended	Not recommended	Not recommended

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes -

Not recommended
Not recommended

Species	Dilution info	Notes
Species Mouse, Rat	Dilution info -	Notes -

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes -

Not recommended
Not recommended

Species	Dilution info	Notes
Species Mouse, Rat	Dilution info -	Notes -

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes -

Not recommended
Not recommended

Species	Dilution info	Notes
Species Mouse, Rat	Dilution info -	Notes -

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes -

Not recommended
Not recommended

Species	Dilution info	Notes
Species Mouse, Rat	Dilution info -	Notes -

Tested
Tested

Species	Dilution info	Notes
Species Human	Dilution info -	Notes -

Not recommended
Not recommended

Species	Dilution info	Notes
Species Mouse, Rat	Dilution info -	Notes -

Associated Products

Select an associated product type

2 products for Alternative Version

Target data

See full target information CXCL9

Function

Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3.

Alternative names

CMK, MIG, SCYB9, CXCL9, C-X-C motif chemokine 9, Gamma-interferon-induced monokine, Monokine induced by interferon-gamma, Small-inducible cytokine B9, HuMIG

Recommended products

Rabbit Recombinant Monoclonal CXCL9 antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P, Flow Cyt (Intra) and reacts with Human samples.

Key facts

Isotype: IgG
Host species: Rabbit
Storage buffer: pH: 7.2 - 7.4
Constituents: 100% PBS
Form: Liquid
Clonality: Monoclonal
Immunogen: The exact immunogen used to generate this antibody is proprietary information.
Carrier free: Yes
Clone number: EPR26512-118
Purification technique: Affinity purification Protein A
Specificity: This antibody does not cross-react with CXCL10, CXCL11, or CXCL2 protein.
Concentration

Storage

Shipped at conditions: Blue Ice
Appropriate short-term storage conditions: +4°C
Appropriate long-term storage conditions: +4°C

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.

This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

This product is compatible with the Maxpar^® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar^® is a trademark of Fluidigm Canada Inc.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CXCL9 also known as MIG (monokine induced by gamma interferon) is a small cytokine protein with a molecular weight of approximately 13 kDa. CXCL9 exhibits strong chemotactic properties and is secreted by various cells including endothelial cells macrophages and fibroblasts upon stimulation by interferon-gamma. Its expression primarily occurs in inflamed tissues and is associated with immune responses. Researchers often use tools like a CXCL9 ELISA kit or CXCL9 test to measure its expression levels in biological samples aiding in understanding its role in various conditions.

Biological function summary

This cytokine plays a pivotal role in the immune system by regulating leukocyte trafficking. CXCL9 exerts its function through binding to the CXCR3 receptor attracting T cells towards sites of inflammation or infection. This interaction is significant in mediating immune surveillance and host defense. CXCL9 does not form part of a larger protein complex but its chemokine activity is critical for immune system coordination. Scientific studies often highlight its involvement through CXCL9 function and expression analysis.

Pathways

CXCL9 significantly influences the chemokine signaling pathway and the Th1-type adaptive immune response. Within these pathways it interacts closely with other chemokines like CXCL10 and CXCL11 which also bind to the CXCR3 receptor. These pathways highlight the coordinated mobilization of T cells during immune challenges and inflammation emphasizing how CXCL9 is often examined alongside these related chemokines in research settings.

Associated diseases and disorders

CXCL9 is notably associated with autoimmune diseases such as rheumatoid arthritis and inflammatory conditions like psoriasis. Its elevated expression is often observed in affected tissues contributing to disease pathogenesis through T cell migration and activation. In these contexts CXCL9 is frequently examined alongside other pro-inflammatory cytokines such as interferon-gamma and TNF-alpha which are known to modulate its expression and activity impacting disease progression and therapeutic strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

10 product images

Western blot - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time: 7.75 seconds.
The expression of CXCL9 is upregulated in response to TNF gamma and LPS treatment (PMID:12946268, 20650898).
All lanes: Western blot - Anti-CXCL9 antibody [EPR26512-118] (Anti-CXCL9 antibody [EPR26512-118] ab290643) at 1/1000 dilution
Lane 1: Untreated THP-1 (human monocytic leukemia monocyte) whole cell lysate at 20 µg
Lane 2: THP-1 treated with 200ng/ml IFN gamma and 50 ng/ml LPS(Lipopolysaccharide) for 24 hours whole cell lysate at 20 µg
Secondary
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
Western blot - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time: 5.5 seonds.
The expression of CXCL9 is upregulated in response to IFN gamma and TNF alpha treatment (PMID:12946268, 20650898).
All lanes: Western blot - Anti-CXCL9 antibody [EPR26512-118] (Anti-CXCL9 antibody [EPR26512-118] ab290643) at 1/1000 dilution
Lane 1: Untreated KATO III (human gastric carcinoma) whole cell lysate at 20 µg
Lane 2: KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate at 20 µg
Secondary
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
Western blot - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time: 10 seonds.
This antibody does not cross-react with CXCL10, CXCL11, or CXCL2 protein.
All lanes: Western blot - Anti-CXCL9 antibody [EPR26512-118] (Anti-CXCL9 antibody [EPR26512-118] ab290643) at 1/1000 dilution
Lane 1: HEK-293T (human embryonic kidney) cells transfected with a human CXCL9 expression vector containing a myc-His tag whole cell lysate at 4 µg
Lane 2: HEK-293T cells transfected with a human CXCL10 expression vector containing a myc-His tag whole cell lysate at 20 µg
Lane 3: HEK-293T cells transfected with a human CXCL11 expression vector containing a myc-His tag whole cell lysate at 40 µg
Lane 4: HEK-293T cells transfected with a human CXCL2 expression vector containing a myc-His tag whole cell lysate at 20 µg
Secondary
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
Exposure time: 10s
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue labelling CXCL9 with Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/100 dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). Positive staining on human lung carcinoma. The section was incubated with Anti-CXCL9 antibody [EPR26512-118] ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND^® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human prostate carcinoma tissue labelling CXCL9 with Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/100 (5.38 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Positive staining on human prostate carcinoma. The section was incubated with Anti-CXCL9 antibody [EPR26512-118] ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND^® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Immunoprecipitation - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
CXCL9 was immunoprecipitated from 0.35 mg KATO III (human gastric carcinoma) treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate 10 ug with Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/30 dilution. Western blot was performed on the immunoprecipitate using Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: KATO III (human gastric carcinoma) treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate 10 ug
Lane 2: Anti-CXCL9 antibody [EPR26512-118] ab290643 IP in KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate
Lane 3:Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-CXCL9 antibody [EPR26512-118] ab290643 in KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3.25 seconds
All lanes: Immunoprecipitation - Anti-CXCL9 antibody [EPR26512-118] (Anti-CXCL9 antibody [EPR26512-118] ab290643)
Predicted band size: 14 kDa
Observed band size: 14 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Panel A THP-1 cell tissue labelling CXCL9 with Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/2000 (0.269 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Positive staining on (A) THP-1 cells treated with a combination of IFN-γ (200ng/ml, 24h) and LPS (50ng/ml, 24h); no staining on (B) untreated THP-1 cells. The section was incubated with Anti-CXCL9 antibody [EPR26512-118] ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND^® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond^® Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human cerebrum tissue labelling CXCL9 with Anti-CXCL9 antibody [EPR26512-118] ab290643 at 1/100 (5.38 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Negative control: no staining on human cerebrum. The section was incubated with Anti-CXCL9 antibody [EPR26512-118] ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND^® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
Flow Cytometry (Intracellular) - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.
Intracellular flow cytometric analysis of 4% paraformaldehyde, 90% methanol THP-1 (Human monocytic leukemia monocyte) treated with 200ng/ml IFN gamma and 50ng/ml LPS for 24h (Right) labelling CXCL9 with Anti-Frizzled 6 antibody [EPR25319-149] (BSA and Azide free) ab290743 at 1/50 dilution/ Untreated control (Left). Goat Anti-Rabbit IgG (Alexa Fluor^® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/2000 dilution was used as a secondary antibody.
Immunocytochemistry/ Immunofluorescence - Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free (ab290654)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized KATO III (Human stomach spherical) cells labelling CXCL9 with primary antibody anti-CXCL9 (Anti-CXCL9 antibody [EPR26512-118] ab290643) at 1/50 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) secondary antibody at 1/1000 dilution. Confocal image showing increased cytoplasmic staining in KATO III cells treated with IFN gamma (human) (100 ng/ml) and TNF alpha (human) (100 ng/ml) for 16 hours. Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) (Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889) was used to counterstain tubulin at 1/200 dilution. The nuclear counter stain is DAPI (blue).
This data was developed using Anti-CXCL9 antibody [EPR26512-118] ab290643, the same antibody clone in a different buffer formulation.